Bank of America’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-29,255
| Closed | -$975K | – | 8620 |
|
|
2024
Q3 | $975K | Sell |
29,255
-46,780
| -62% | -$1.61M | ﹤0.01% | 5071 |
|
|
2024
Q2 | $2.06M | Sell |
76,035
-15,289
| -17% | -$302K | ﹤0.01% | 4424 |
|
|
2024
Q1 | $1.97M | Buy |
91,324
+72,788
| +393% | +$1.59M | ﹤0.01% | 4461 |
|
|
2023
Q4 | $112K | Buy |
18,536
+5,663
| +44% | +$28.2K | ﹤0.01% | 6334 |
|
|
2023
Q3 | $71.6K | Buy |
12,873
+889
| +7% | +$5.72K | ﹤0.01% | 6380 |
|
|
2023
Q2 | $88K | Buy |
+11,984
| New | +$90.7K | ﹤0.01% | 6252 |
|
|
2023
Q1 | – | Sell |
-11
| Closed | -$36 | – | 8702 |
|
|
2022
Q4 | $36 | Sell |
11
-5,728
| -100% | -$23K | ﹤0.01% | 7866 |
|
|
2022
Q3 | $21K | Sell |
5,739
-8,084
| -58% | -$29.9K | ﹤0.01% | 7023 |
|
|
2022
Q2 | $43K | Sell |
13,823
-11,544
| -46% | -$53.1K | ﹤0.01% | 6914 |
|
|
2022
Q1 | $135K | Buy |
25,367
+1,842
| +8% | +$8.74K | ﹤0.01% | 6704 |
|
|
2021
Q4 | $115K | Buy |
23,525
+7,453
| +46% | +$50.7K | ﹤0.01% | 6823 |
|
|
2021
Q3 | $142K | Buy |
+16,072
| New | +$148K | ﹤0.01% | 6523 |
|
|
2021
Q2 | – | Sell |
-404
| Closed | -$7K | – | 8458 |
|
|
2021
Q1 | $7K | Buy |
+404
| New | +$6.61K | ﹤0.01% | 7090 |
|
Bank of America's LBPH Position: Q4 2024 in Review
Bank of America sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 29,255 shares — an estimated $975K sold.
Bank of America first reported a position in LBPH in Q1 2021 and held it in 13 quarters. The position peaked at $2.06M in Q2 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Bank of America reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Bank of America sold 29,255 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $975K.
- Bank of America first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Bank of America's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $2.06M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.